SPDR S&P Biotech ETF (NYSEARCA:XBI | XBI Price Prediction) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from cap-weighted peers and creates both opportunity and risk that investors need to understand clearly right now.
The fund carries over $8 billion in assets across 150+ holdings, with 96% of the portfolio in healthcare. XBI is up about 2% year to date, but that calm surface masks a rougher month: shares pulled back roughly 4% over the past 30 days. The one-year picture is far more compelling, with the fund up 46% over the past year. Zoom out five years, though, and the fund is still down about 6%, a reminder of how brutal the 2021-2022 rate-driven selloff was for biotech.
The FDA’s New Leadership Changes the Calculus for Every Holding
The single biggest macro factor shaping XBI’s next 12 months is the FDA regulatory environment under its new leadership. Marty Makary was confirmed as FDA Administrator, resolving genuine uncertainty about who would run the agency. That clarity matters because biotech valuations are built almost entirely on the probability of regulatory approval, and an unpredictable FDA is a discount rate in itself.
The concern now is not who sits at the top but what is happening beneath. DOGE-related staffing reductions and broader HHS restructuring have raised questions about review capacity and advisory committee continuity. A slower approval pipeline would compress valuations across XBI’s 150+ holdings simultaneously, hitting small and mid-cap names hardest because they have no commercial revenue to cushion the blow.
Watch the FDA’s published PDUFA action dates and advisory committee calendars monthly. A pattern of delays or unexpected refusals would be the clearest warning sign. A steady approval cadence through mid-2026 would confirm that operational disruption has been contained.
Equal Weight Means Every Clinical Readout Hits the Whole Fund
Because each holding starts at roughly the same portfolio weight, a single binary clinical event, whether a phase 3 success or failure, moves the fund in a way that a cap-weighted index would barely register.
Several holdings have high-stakes readouts coming. Moderna (NASDAQ:MRNA), currently the fund’s largest position at about 2.3% weight, expects phase 3 norovirus and adjuvant melanoma data in 2026. Moderna is up about 82% year to date, driven partly by a patent settlement that sparked a sharp sentiment reversal on Reddit. A post on r/wallstreetbets titled “Moderna +10% after-hours as Moderna agrees to pay up to $2.25B to settle COVID vaccine patent dispute” captured the mood shift, accumulating 270 upvotes by March 5.
Krystal Biotech (NASDAQ:KRYS) is the fund’s quiet fundamental standout, posting 94% gross margins and $204 million in net income for full-year 2025, with VYJUVEK revenue growing 34% year over year. Phase 3 readouts in corneal DEB and neurotrophic keratitis are both expected before year-end.
Sarepta Therapeutics (NASDAQ:SRPT) is attempting a recovery after ELEVIDYS revenue fell 33% year over year in Q4 2025 following a safety-driven suspension of non-ambulatory shipments. Management expects to return to profitability in 2026, but the path depends on label rehabilitation and a Japan launch that began in February.
The quarterly rebalance is where this mechanic becomes most visible. XBI rebalances in March, June, September, and December, equalizing weights each time: strong performers get trimmed and beaten-down names get topped up. Watch the holdings file after each rebalance to see which names gained or lost weight, particularly whether high-burn, pre-revenue names like Recursion Pharmaceuticals (NASDAQ:RXRX), down 23% year to date amid dilution concerns from a $300 million ATM equity offering, are being added to or reduced from the portfolio.
If the FDA maintains consistent review timelines through mid-2026 and the June rebalance does not materially increase exposure to high-burn names with no near-term catalysts, XBI’s one-year momentum has a credible foundation. If either condition breaks, the equal-weight structure that amplified the upside will amplify the downside just as efficiently.
Top Gaining Stocks
Top Losing Stocks